Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma.

Details

Ressource 1Download: ncrna-07-00005-v2.pdf (1994.62 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_624A54C72BF4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma.
Journal
Non-coding RNA
Author(s)
Tusup M., Cheng P.F., Picardi E., Raziunaite A., Dummer R., Levesque M.P., French L.E., Guenova E., Kundig T.M., Pascolo S.
ISSN
2311-553X (Electronic)
ISSN-L
2311-553X
Publication state
Published
Issued date
12/01/2021
Peer-reviewed
Oui
Volume
7
Number
1
Pages
E5
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
RNA editing is a highly conserved posttranscriptional mechanism that contributes to transcriptome diversity. In mammals, it includes nucleobase deaminations that convert cytidine (C) into uridine (U) and adenosine (A) into inosine (I). Evidence from cancer studies indicates that RNA-editing enzymes promote certain mechanisms of tumorigenesis. On the other hand, recoding editing in mRNA can generate mutations in proteins that can participate in the Major Histocompatibility Complex (MHC) ligandome and can therefore be recognized by the adaptive immune system. Anti-cancer treatment based on the administration of immune checkpoint inhibitors enhance these natural anti-cancer immune responses.
Based on RNA-Seq datasets, we evaluated the editome of melanoma cell lines generated from patients pre- and post-immunotherapy with immune checkpoint inhibitors. Our results reveal a differential editing in Arthrobacter luteus (Alu) sequences between samples pre-therapy and relapses during therapy with immune checkpoint inhibitors.
These data pave the way towards the development of new diagnostics and therapies targeted to editing that could help in preventing relapses during immunotherapies.
Keywords
ADAR, Alu sequences, editing, immune checkpoint inhibitors, immunotherapy, melanoma
Pubmed
Web of science
Open Access
Yes
Create date
26/01/2021 15:37
Last modification date
10/04/2021 6:33
Usage data